Literature DB >> 12396605

Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef.

L Jean Patterson1, Nina Malkevitch, Jun Zhao, Bo Peng, Marjorie Robert-Guroff.   

Abstract

Vaccines incorporating multiple HIV components should elicit broad immunity and protection against a spectrum of HIV strains. Early regulatory and accessory gene products are attractive candidates for such vaccines. Here, immunogenicity studies on SIV Rev and Nef expressed in replication competent Adenovirus type 5 host range mutant vectors (Ad5hr) are summarized. Interferon-gamma (IFN-gamma)-secreting cells in response to Env and Rev peptides were enumerated by ELISPOT after two sequential immunizations of 55 macaques with Ad5hr-SIVenv/rev. Responses to SIV Nef were assessed in 16 macaques also immunized with Ad5hr-SIVnef. Potent cellular immunity to both Rev and Nef was induced following the second Ad-recombinant immunization and persisted for at least 30 weeks. Persistent cellular immunity to SIV Env was also seen, with a mean of 700 IFN-gamma-secreting cells per million PBMC. Rev and Env responses were positively correlated. While greater responses to early gene products occur in natural infection, as immunogens Rev and Nef elicited the same number of IFN-gamma secreting cells as Env, after adjusting for differences in protein size. The same percentage of macaques also responded to Rev, Nef, and Env: 59, 63, and 64%, respectively. Overall, Ad5hrSIVenv/rev and -SIVnef were highly effective immunogens. Their contribution to protective efficacy will be addressed in future studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12396605     DOI: 10.1089/104454902760330165

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  6 in total

1.  Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.

Authors:  Gerald V Quinnan; Xiao-Fang Yu; Mark G Lewis; Peng Fei Zhang; Gerd Sutter; Peter Silvera; Ming Dong; Anil Choudhary; Phuong T N Sarkis; Peter Bouma; Zhiqiang Zhang; David C Montefiori; Thomas C Vancott; Christopher C Broder
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice.

Authors:  Christopher Palma; Michael G Overstreet; Jean-Marc Guedon; Egbert Hoiczyk; Cameron Ward; Kasey A Karen; Fidel Zavala; Gary Ketner
Journal:  Vaccine       Date:  2011-01-01       Impact factor: 3.641

3.  Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.

Authors:  Michael G Berg; Robert J Adams; Ratish Gambhira; Mark C Siracusa; Alan L Scott; Richard B S Roden; Gary Ketner
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

Review 4.  Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Authors:  L Jean Patterson; Marjorie Robert-Guroff
Journal:  Expert Opin Biol Ther       Date:  2008-09       Impact factor: 4.388

5.  Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.

Authors:  Jun Zhao; Joel Pinczewski; Victor R Gómez-Román; David Venzon; V S Kalyanaraman; Phillip D Markham; Kristine Aldrich; Matthew Moake; David C Montefiori; Yuanmei Lou; George N Pavlakis; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 6.  Adenoviruses as vaccine vectors.

Authors:  Nia Tatsis; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2004-10       Impact factor: 11.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.